• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Addition of glyburide in mild GDM-is there benefit?

image_pdfFavoriteLoadingFavorite

FINDINGS:

Women with gestational diabetes, controlled with diet, were randomized to receive placebo or glyburide. Primary outcome was a decrease in birth weight of 200g.  Secondary maternal outcomes included need for insulin and associated adverse outcomes such as chorioamnionitis, pregnancy-induced hypertension, need for operative delivery, shoulder dystocia and third and fourth degree perineal lacerations.  Secondary newborn outcomes included small for gestational age (SGA) and large for gestational age (LGA), as well as birth trauma, hypoglycemia, umbilical artery pH of less than or equal to 7 and high bilirubin.

  • There was no difference in birthweight between the glyburide and placebo groups
  • There was no difference in maternal adverse outcomes although the study was not adequately powered to detect differences in rare events such as shoulder dystocia
  • There was no difference in adverse neonatal outcomes
  • Diet therapy alone with regular glucose monitoring is the appropriate management plan for mild gestational diabetes

SYNOPSIS:

Diet control for the treatment of mild gestational diabetes is known to reduce birthweight and is the mainstay of therapy.  The authors, in a well-designed randomized controlled study, set out to determine if adding glyburide would further decrease birthweight which is associated with adverse outcomes such as birth trauma, shoulder dystocia and neonatal hypoglycemia (Obstet Gynecol 2015).  Women with mild gestational diabetes (fasting glucose below 105/mg/dL with at least 2 elevated values on the 3 hour glucose tolerance test) using the National Diabetes Data Group criteria were randomized into glyburide and placebo groups.  Even though this study demonstrated that glycemic profiles were significantly improved with the addition of glyburide, there was no additional benefit with the addition of glyburide to diet therapy.

KEY POINTS:

  • Gestational diabetes is a common problem in pregnancy which can result in significant maternal and neonatal complications
  • Diet therapy and glucose monitoring reduce the risk of LGA which is a cause of both maternal and newborn complications
  • Maternal weight gain during pregnancy is an important risk factor for LGA

Learn More – Primary Sources:

Glyburide in Women With Mild Gestational Diabetes: A Randomized Controlled Trial

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Practical obstetrics info for your women's healthcare practice
Gestational Diabetes Mellitus – Definitions, Risk Factors and Complications
Practical obstetrics info for your women's healthcare practice
What Is The ‘One-Step’ GDM Screening Approach?
Practical obstetrics info for your women's healthcare practice
Screening for Gestational Diabetes: The ‘2 Step’ Approach
Practical obstetrics info for your women's healthcare practice
GDM and Postpartum Followup – The ‘When and How’ of Screening
Levels of Evidence – How to Rate the Quality of a Study
Practical info on evidence based medicine for your women's healthcare practice

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site